X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA JUBILANT LIFE SCIENCES GSK PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 62.9 29.3 214.7% View Chart
P/BV x 10.1 6.0 168.0% View Chart
Dividend Yield % 1.3 0.3 414.2%  

Financials

 GSK PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
JUBILANT LIFE SCIENCES
Mar-14
GSK PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs3,838187 2,054.6%   
Low Rs2,63765 4,050.7%   
Sales per share (Unadj.) Rs354.2364.3 97.2%  
Earnings per share (Unadj.) Rs39.86.8 580.9%  
Cash flow per share (Unadj.) Rs42.924.5 175.0%  
Dividends per share (Unadj.) Rs30.003.00 1,000.0%  
Dividend yield (eoy) %0.92.4 38.9%  
Book value per share (Unadj.) Rs236.9164.9 143.7%  
Shares outstanding (eoy) m84.70159.28 53.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.3 2,644.2%   
Avg P/E ratio x81.418.4 442.5%  
P/CF ratio (eoy) x75.55.1 1,468.9%  
Price / Book Value ratio x13.70.8 1,788.9%  
Dividend payout %75.443.8 172.2%   
Avg Mkt Cap Rs m274,21620,061 1,366.9%   
No. of employees `0004.76.2 75.9%   
Total wages/salary Rs m4,83011,052 43.7%   
Avg. sales/employee Rs Th6,387.09,383.0 68.1%   
Avg. wages/employee Rs Th1,028.31,786.9 57.5%   
Avg. net profit/employee Rs Th717.1176.3 406.7%   
INCOME DATA
Net Sales Rs m30,00058,034 51.7%  
Other income Rs m728191 382.1%   
Total revenues Rs m30,72858,224 52.8%   
Gross profit Rs m4,1905,786 72.4%  
Depreciation Rs m2632,812 9.4%   
Interest Rs m03,237 0.0%   
Profit before tax Rs m4,655-72 -6,456.3%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4572,145 21.3%   
Tax Rs m1,744696 250.4%   
Profit after tax Rs m3,3681,090 308.9%  
Gross profit margin %14.010.0 140.1%  
Effective tax rate %37.5-965.9 -3.9%   
Net profit margin %11.21.9 597.5%  
BALANCE SHEET DATA
Current assets Rs m16,74229,280 57.2%   
Current liabilities Rs m7,20238,912 18.5%   
Net working cap to sales %31.8-16.6 -191.6%  
Current ratio x2.30.8 308.9%  
Inventory Days Days5284 61.4%  
Debtors Days Days2151 41.0%  
Net fixed assets Rs m8,63555,712 15.5%   
Share capital Rs m847155 548.2%   
"Free" reserves Rs m19,22220,968 91.7%   
Net worth Rs m20,06926,265 76.4%   
Long term debt Rs m1017,169 0.1%   
Total assets Rs m30,03888,606 33.9%  
Interest coverage xNM1.0-  
Debt to equity ratio x00.7 0.1%  
Sales to assets ratio x1.00.7 152.5%   
Return on assets %11.24.9 229.6%  
Return on equity %16.84.2 404.2%  
Return on capital %25.511.6 220.1%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m52822,004 2.4%   
Fx outflow Rs m7,19311,749 61.2%   
Net fx Rs m-6,66510,255 -65.0%   
CASH FLOW
From Operations Rs m2,3608,026 29.4%  
From Investments Rs m3,008-1,744 -172.5%  
From Financial Activity Rs m-5,108-4,447 114.8%  
Net Cashflow Rs m2601,834 14.2%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 50.7 3.5 1,448.6%  
Indian inst/Mut Fund % 10.2 8.7 117.2%  
FIIs % 23.8 21.2 112.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.1 73.0%  
Shareholders   102,036 23,815 428.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS